United Therapeutics Corporation (UTHR) stock closed Tuesday’s session at $199.30 and gained 0.36%. The stock volume traded was 0.41 million shares, slightly higher than the average daily volume of 0.4 million shares within the past 50 days. UTHR shares have risen by 102.85% over the last 12 months, and they have moved up by 3.99% in the past week. The UTHR stock has gained 18.61% over the past three months. The company is currently valued at $8.76 billion in the market and its outstanding shares stood at 44.50 million.
United Therapeutics’ existing and developing product offerings
United Therapeutics Corporation is a biotechnology company that focuses on the design, development and commercialization of therapeutic products. These treatments are to meet the unmet medical needs of patients that have chronic and life-threatening diseases in the US and around the world.
The company already has a set of therapies that are commercially ready and are rolling out. These include:
- Remodulin- helps get rid of symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients
- Tyvaso- helps enhance the exercise ability in PAH patients (inhaled formula)
- Orenitram- helps support the exercise ability in PAH patients (tablet dosage)
- Unituxin- for treatment of high-risk neuroblastoma
- Adcirca- enhances the exercise capacity in PAH patients (oral formula)
UTHR stock has a subsidiary that is wholly owned by the name of Lung Biotechnology PBC. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotech company. The operations of this subsidiary are aimed at addressing the acute shortage of transplantable lungs nation-wide. There is also focus on a numerous technologies that either delays the need for organs that have shortages or increases their supply.
Latest Tyvaso® approval by FDA for PAH patients
In 2009, the United Therapy drug known as Tyvaso® was first approved for its treatment of pulmonary arterial hypertension (PAH) in order to improve the ability to exercise. On 1st April 2021, UTHR stock announced that the second round of approval of Tyvaso® has been approved to be used as a treprostinil-based inhalation solution that is used for specific pulmonary arterial hypertension patients which is associated with interstitial lung disease (ILD).
Tyvaso® and Remodulin sale growth can rally UTHR stock for 2021
Rolling out of Tyvaso® will be landmark news for the vulnerable patient population. Pulmonary Hypertension worsens the health of a patient affected with ILD especially if the patients have severe-ILD (PH affects 86% of patients with serious-ILD). The president of United Therapeutics states that advancement in the launch of this indication will be done with a sense of urgency as the company expands field-based teams by 40% to raise awareness among the ILD community.
By the end of 2022, UTHR stock is expecting that uptake of Tyvaso® in the indication will double the number of patients on its therapy.
The sales or Remodulin have slightly slumped since 2018 due to competition but the company is looking forward to launch the Remodulin delivery-device, Remunity pump this year. This device will function similarly to diabetic patients’ insulin pumps. Once this market of insulin pumps is penetrated along with commercialized launch of Tyvaso®, UTHR stock will see positive growth due to growth or at least stability in Remodulin sales.